Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Addex Therapeutics Ltd., a foreign private issuer based in Geneva, Switzerland, for the month of November 2023. The filing, dated November 8, 2023, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document acts as a conduit for a press release rather than a financial statement.
Material Changes
No material financial changes versus prior periods are detailed in the text of this filing. The document solely references the issuance of a press release without summarizing its content.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, or specific risk factors. It directs readers to the attached press release (Exhibit 99.1) for the substance of the announcement. The filing notes that the press release is incorporated by reference into the company's Form F-3 and Form S-8 registration statements.
Key Facts for Investor Verification
- Review the full text of the press release dated November 8, 2023 (Exhibit 99.1), as the specific news or operational update is not summarized in this filing.
- Verify the impact of the press release announcement on the company's Form F-3 and Form S-8 registration statements.
- Confirm the identity of the signatory, Tim Dyer, Chief Executive Officer, who authorized the report.